Evaluation of Dipyridamole in Preventing Post-Transplant Hypophosphatemia in Kidney Transplant Recipients

Part of paid clinical trials in Stanford, California.

Sponsor
Stanford University
Study ID
NCT06824454
Phase
PHASE2
Status
Recruiting
Apply to this trial

Conditions

  • Hypophosphatemia
  • Kidney Transplantation

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Dipyridamole 75 MG — DRUG
    Dipyridamole administered three times daily when serum phosphorus levels fall below 4 mg/dL. The drug is used off-label for this study to manage hypophosphatemia in kidney transplant recipients.

Study Details

The primary goal is to determine if Dipyridamole can improve serum phosphate levels and reduce the need for phosphate supplementation.

Key Dates

Start date
May 15, 2025
Status verified
Jun 2026
Primary completion
May 31, 2027
Completion
May 31, 2027

Study Design

Enrollment
90 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: Treatment Group
    Participants receive Dipyridamole in addition to standard post-transplant care.
  • No Intervention: Control Group
    Participants in this group will receive standard post-transplant care without Dipyridamole.

Primary Outcome Measure

Change in Serum Phosphorus Levels After Dipyridamole Administration [ Time Frame: Baseline, 1 week, 4 weeks, 8 weeks, 12 weeks, and after stopping medicatio ]

Locations (1)

FacilityCityStateZIPSite coordinators
Stanford UniversityStanfordCalifornia94304
Pari Waghela, MS
[email protected]
650-724-8441
Stephan Busque, MD (PRINCIPAL_INVESTIGATOR)

Find similar trials in Stanford, CA

By research site
Stanford University· Stanford, CA

Related Studies